Evonik stock at EUR 20.60, down 0.87% before Xetra
Published on 11/11/2026 at 07:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat Moves Evonik Stock Next
- Evonik is presenting new Specialty Nutrition products at EuroTier through November 13.
- Third-quarter adjusted EBITDA rose 40 percent to EUR 629 million, while full-year guidance moved toward the upper half of the EUR 2.0 billion to EUR 2.2 billion range.
- The company plans to preview its ZyneXtra program ahead of a planned first-quarter 2027 launch.
Evonik stock traded at EUR 20.60 on Lang & Schwarz at 07:45 Berlin time on Wednesday, November 11, 2026, 0.87 percent below the Xetra close of Tuesday, November 10, 2026 at EUR 20.78.
Product Push Meets Stronger Outlook
Evonik is using EuroTier 2026 in Hanover to showcase its MetAMINO nutrition platform and introduce Lypron and ZyneXtra. The company said the event runs through November 13, with live demonstrations of its AMINONIR analysis service and the enhanced AMINODat platform. Its press release says ZyneXtra is planned for launch in the first quarter of 2027.
The group entered the event after a stronger third quarter. According to European Coatings, adjusted EBITDA increased 40 percent year on year to EUR 629 million and revenue rose 13 percent. Evonik now expects full-year 2026 adjusted EBITDA in the upper half of its EUR 2.0 billion to EUR 2.2 billion range. The report also cites EUR 369 million in third-quarter free cash flow, up from EUR 300 million a year earlier.
The earnings picture remains mixed. Restructuring provisions of EUR 313 million contributed to a third-quarter net loss of EUR 53 million, even as operating earnings and cash generation improved. Investors will therefore weigh the stronger operating trend against the cost of the efficiency program and the progress of portfolio measures.
The broader German equity market remains relevant for investors following the DAX.
More news and analyses are available on Evonik stock.
